263 related articles for article (PubMed ID: 31055223)
1. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
3. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
4. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
[TBL] [Abstract][Full Text] [Related]
5. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
7. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
8. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.
Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L
J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
10. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
11. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
12. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
[TBL] [Abstract][Full Text] [Related]
13. Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume.
Caldwell JZK; Cummings JL; Banks SJ; Palmqvist S; Hansson O
Alzheimers Res Ther; 2019 Dec; 11(1):109. PubMed ID: 31878968
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
15. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
[TBL] [Abstract][Full Text] [Related]
16. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.
Handoko M; Grant M; Kuskowski M; Zahs KR; Wallin A; Blennow K; Ashe KH
JAMA Neurol; 2013 May; 70(5):594-9. PubMed ID: 23479202
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
19. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
20. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
